12/03/2025
✨ New Journal Publication! ✨
Huge news for breastfeeding mothers with ADHD — our study on atomoxetine is published!
Our study shows that only very small amounts of atomoxetine enter breast milk. Most mothers had an RID under 0.2%, and even the highest level found was only 0.65%, suggesting very low risk while breastfeeding.
Because of this new evidence, we are updating atomoxetine’s lactation safety rating from L4 to L2, reflecting a much safer profile than previously thought.
A few reports of infant fussiness have been noted, so monitoring is still important. Any concerns should be reported to systems like FAERS to help strengthen safety data.
This research provides encouraging evidence that atomoxetine may be a safe, viable ADHD treatment for breastfeeding mothers.
https://journals.lww.com/psychopharmacology/fulltext/9900/atomoxetine_as_a_viable_adhd_treatment_in.482.aspx #:~:text=Conclusions:,of%20ADHD%20in%20lactating%20women.
